Gene methylation of oestrogen and epidermal growth factor receptors in neoplastic and perineoplastic breast tissues. by Petrangeli, E. et al.
Brtsh Jounal ofCancer(1995)72, 973-975
© 1995 Stockton Press All rights reserved 0007-0920/95 $12.00
SHORT COMMUNICATION
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Summary Oestrogen receptor (ER) and epidermal growth factor receptor (EGFR) gene methylation was
evaluated in neoplastic and perineoplastic breast tissues from 20 patients. In both tissues, ER gene methylation
was inversely correlated with protein levels, while EGFR gene methylation was not. A preferential ER gene
hypomethylation was found in neoplastic tissues, suggesting a significant role in neoplastic transformation.
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Oestrogen and growth factors are involved in regulating
breast cell growth through interaction with specific receptors.
Several studies have demonstrated that oestrogen and epi-
dermal growth factor (EGF)-stimulated pathways are closely
connected. Oestrogen treatment causes increases in secretion
of EGF and EGF-related peptides by human breast cancer
cell lines (Mori et al., 1988), and increase of EGFR express-
ion in rat uterus (Lingham et al., 1988) and in a breast
cancer cell line (Berthois et al., 1989). An inverse correlation
between EGFR levels and both oestrogen receptor (ER) and
progesterone receptor (PR) was demonstrated in human
breast cancer (for review see Klijn et al., 1992).
Our previous studies demonstrated overexpression of ERs
and PRs in neoplastic tissues, as compared with perineo-
plastic tissues (Petrangeli et al., 1994). DNA methylation at
the 5' position of cytosine residues is an important
mechanism which may regulate gene expression (Cedar and
Razin, 1990). In fact, an inverse relationship between
methylation and expression has been demonstrated for many
genes, indicating an important role for gene methylation in
repression of transcription (Doerfler, 1983). A fundamental
role for DNA methylation in neoplastic transformation has
been suggested. Goelz et al. (1985) demonstrated that DNA
from both benign colon polyps and malignant carcinomas
was hypomethylated, suggesting that an alteration of DNA
methylation could be a key event in the initiation of neo-
plasia. Some chemical carcinogens are able to inhibit DNA
methylation and to activate gene expression (Jones and Buck-
ley, 1990).
Here we report a comparison between the methylation
state of ER and EGFR genes and their expression in neo-
plastic and non-malignant perineoplastic tissues to investigate
whether (1) the hypomethylation of these genes is associated
with their expression and (2) if it is involved in neoplastic
transformation.
Materials and methods
Patients
Twenty patients with primary breast cancer were evaluated.
During surgery, approximately 1 cm3 of both tumoral (20
samples) and perineoplastic tissues (16 samples) were coll-
ected and stored in liquid nitrogen. Histology demonstrated
normal features in all perineoplastic tissues examined. Halfof
the sample was used for simultaneous determination of ER,
PR and EGFR. The remainder was used as a source of
genomic DNA.
Steroid receptor assay
ER and PR were measured in cytosol and nuclear extracts by
enzyme immunoassay (Abbott ER-EIA and PR-EIA mono-
clonal kits) and expressed as fmol mg-' protein in the cytosol
or as fmol mg' DNA in the nuclei.
Membrane EGFR binding assay
Binding of EGF was determined by a modification of the
radioligand method of Birman et al. (1987).
Gene methylation
1OiLg of extracted DNA was digested with restriction
enzymes, separated on 0.8% agarose gel, transferred to nylon
filters and hybridised with cDNA probes labelled with 32P-
dCTP by random priming. The plasmid pOR3 including
1.3 Kb of the human ERcDNA in the EcoRI site ofpBR322,
donated by P Chambon (Green et al., 1986) was used as a
source of ER probe. EGFR cDNA was kindly provided by P
Di Fiore (Di Fiore et al., 1987). The methylation of ER and
EGFR genes was evaluated using HpaII and MspI restriction
enzymes, both recognising the same CCGG sequences. The
difference between the two restriction patterns shows the
methylation status, as only MspI will cleave when internal
cytosine is methylated (van der Ploeg et al., 1980). ER gene
methylation was evaluated on 16 perineoplastic and 20 neo-
plastic samples; for the EGFR gene, we evaluated 14
perineoplastic and 19 neoplastic samples.
Table I ER and EGFR gene hypomethylation incidence in neoplastic
and perineoplastic tissues
Perineoplastic tissues
Neoplastic tissues
P (Mann-Whitney U-test)
Hypomethylated
ER/total
4/16
14/20
0.009
Hypomethylated
EGFR/total
8/14
10/19
0.828
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Table II Cytosolic (fmol mg-' protein) and nuclear (fmol mg-' DNA) steroid receptors and
EGFR (fmolmg-' membrane protein) levels. Correlation with ER and EGFR gene
methylation
Hypo- Hyper- Hypo- Hyper-
methylated methylated P methylated methylated P
ER ER (t-test) EGFR EGFR (t-test)
ER(C)
Mean 116.8 10.2 0.002 59.9 64.4 0.9082
s.e. 31.7 2.9 23.6 31.1
ER(N)
Mean 247.9 51.4 0.0015 151.3 161.5 0.8873
s.e. 55.2 13.3 52.9 44.2
PR(C)
Mean 162.8 59.2 0.0447 162.4 71.9 0.1043
s.e. 35.5 34.8 44.6 25.4
PR(N)
Mean 185.3 51.4 0.0222 145.7 102.8 0.5111
s.e. 54.3 12.9 55.5 22.8
EGFR
Mean 143.1 577.6 0.0348 380.2 178.2 0.2378
s.e. 58.4 188.7 141.8 68.7
N 18 18 18 15
C, cytosol; N, nuclear extract.
Results
To determine the overall methylation status of ER and
EGFR genes, we used MspI-HpaII restriction analysis.
When the Southern blots were hybridised with the ER probe,
a 3.5 Kb band was always present in MspI-digested samples,
whereas it appeared in the HpaII digestion product only
when the ER gene was hypomethylated. Statistical analysis
shows that ER gene hypomethylation appears more fre-
quently in neoplastic than perineoplastic tissues (Table I)
(Mann-Whitney U-test, P = 0.009). The methylation status
in both tissues was significantly inversely correlated to
cytosolic and nuclear ER levels. We also found a negative
correlation with both cytosolic and nuclear PR levels and a
positive correlation with EGFR levels (Table II). On the
Southern blots hybridised with the EGFR probe, a 4Kb
band was characteristic of hypomethylated EGFR digested
with HpaII. EGFR gene methylation pattern did not differ in
neoplastic or in perineoplastic samples (Table I), neither did
it significantly correlate with EGFR expression (Table II).
Discussion
These data show that ER expression is inversely correlated
with ER gene methylation, suggesting that ER gene methyla-
tion may be a factor determining ER expression in the
breast. PR and EGFR levels are also related to ER methyla-
tion pattern, confirming the strong inter-relationship of their
expression. Furthermore, ER gene hypomethylation occurs in
a significantly higher percentage of tumour tissues relative to
perineoplastic tissues, suggesting that ER gene hypomethy-
lation and subsequent ER protein overexpression could play
a role in neoplastic transformation, leading to enhanced res-
ponsiveness to oestrogenic stimuli. The preferential hyper-
methylation of tissue-specific ER gene present in the
perineoplastic breast tissues is not incompatible with the
hormone dependence of the breast tissue. Previous studies
have indicated that non-neoplastic breast tissues express very
low levels of ER, yet are responsive to oestrogenic stimuli
(Petrangeli et al., 1994). EGFR gene methylation does not
appear to be a fundamental mechanism in controlling its
expression, nor does it seem to play a role in neoplastic
transformation. Thus the hypomethylated EGFR samples did
not show a statistically significant increase of expression of
EGFR relative to hypermethylated samples and we did not
find preferential hypomethylation of EGFR gene in neoplas-
tic vs normal tissues.
Our data on ER gene methylation are in agreement with
many studies on the regulatory function of methylation in
the expression of tissue-specific genes (Doerfler, 1983). DNA
methylation at promoter level might inhibit gene expression
by directly hindering the binding of transcription factors, or
it might promote the interaction of nuclear proteins, which
secondarily prevent the formation of the transcription com-
plex (Boyes and Bird, 1991). In contrast, housekeeping genes
are undermethylated at their 5' ends and are available for
constitutive expression (Bird, 1986). As the EGFR promoter
belongs to a class of housekeeping promoters that lack
typical TATA elements and are characterised by high GC
content (Ishii et al., 1985), the modification of EGFR
methylation could affect a non-promoter region that does not
interfere significantly with the expression of the gene.
In conclusion, ER gene hypomethylation occurs in a large
number of breast cancers and is associated with its enhanced
expression, perhaps through interference at promoter level.
We cannot show at which step of neoplastic transformation
ER gene hypomethylation occurs or whether it exerts a
pivotal or intermediate role. Further studies investigating the
molecular characteristic of ER gene in healthy breast, in
comparison with those observed in progressive breast
diseases, could help us to better clarify the role of ER gene
methylation in neoplastic transformation.
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